Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis.
BACKGROUND
Despite the prominent position of methotrexate (MTX) in Rheumatoid Arthiris (RA) therapeutics, its real-world effectiveness may be influenced by a relative lack of tolerability or other side effects that physicians may not be aware of but that are bothersome to patients. The aim of this study is to identify suboptimal patient experience with MTX and to raise awareness for clinicians to identify opportunities to mitigate bothersome symptoms and side effects and optimize response to MTX.


METHODS
We conducted a prospective, cross-sectional, online survey among RA patients who were members of Creakyjoints, a large arthritis patient community. Eligible participants must have recently initiated a new biologic, subcutaneous (SQ) MTX, or oral MTX in the last 12 months and were uniquely assigned to one of these 3 groups. Descriptive statistics were used to compare patient-reported side effects and tolerability related to MTX use in the 3 medication groups (SQ MTX, oral MTX, and biologic).


RESULTS
A total of 382 (85 %) of 448 eligible patients completed the survey and were grouped as: biologic (n = 218), SQ MTX (n = 49), and oral MTX (n = 115). Demographics were mean standard deviation (SD) age 48 (10) years, 92 % white, 91 % women. Symptoms significantly more prevalent in the SQ and oral MTX groups included diarrhea, fatigue, malaise, and hair loss. Injection related pain was lower with SQ MTX compared to SQ biologics. Out of a total of 8 potential symptoms and side effects examined, higher dose MTX (> = 20 mg/week) was associated with a 2.26 (1.25-4.09) greater likelihood of more side effects referent to < =10 mg/week.


CONCLUSIONS
Results from this real-world RA patient cohort suggest that MTX is accompanied by many patient-reported side effects and tolerability problems that may be under-recognized by physicians. These may impact both treatment satisfaction and medication adherence.
University of Alabama at Birmingham, 510 20th Street South, FOT 802, Birmingham, AL, 35294, USA. jrcurtis@uabmc.edu.
J R
JR
Curtis
University of Alabama at Birmingham, 510 20th Street South, FOT 802, Birmingham, AL, 35294, USA.
F
F
Xie
University of Alabama at Birmingham, 510 20th Street South, FOT 802, Birmingham, AL, 35294, USA.
D
D
Mackey
Global Healthy Living Foundation, Upper Nyack, NY, 10960, USA.
N
N
Gerber
University of Alabama at Birmingham, 510 20th Street South, FOT 802, Birmingham, AL, 35294, USA.
A
A
Bharat
University of Alabama at Birmingham, 510 20th Street South, FOT 802, Birmingham, AL, 35294, USA.
T
T
Beukelman
University of Alabama at Birmingham, 510 20th Street South, FOT 802, Birmingham, AL, 35294, USA.
K G
KG
Saag
University of Alabama at Birmingham, 510 20th Street South, FOT 802, Birmingham, AL, 35294, USA.
L
L
Chen
Global Healthy Living Foundation, Upper Nyack, NY, 10960, USA.
B
B
Nowell
Global Healthy Living Foundation, Upper Nyack, NY, 10960, USA.
S
S
Ginsberg
Adherence; Methotrexate; Rheumatoid arthritis; Side effects
Ann Rheum Dis. 2005 Feb;64(2):207-11
15208176
Int J Rheum Dis. 2010 Oct;13(4):e83-4
21199461
Ann Rheum Dis. 2014 Aug;73(8):1549-51
24728329
Clin Rheumatol. 2014 May;33(5):609-14
24609758
Ann Rheum Dis. 2003 May;62(5):423-6
12695153
Ann Rheum Dis. 2009 Jul;68(7):1094-9
19033290
Ann Rheum Dis. 2010 Apr;69(4):671-6
19740904
Expert Rev Med Devices. 2014 Sep;11(5):447-55
24934630
Am J Epidemiol. 2014 Apr 1;179(7):917-26
24569640
Curr Med Res Opin. 2011 Jan;27(1):71-8
21091097
J Am Acad Dermatol. 2005 Oct;53(4):652-9
16198787
Arthritis Rheum. 2013 Aug;65(8):1985-94
23686414
Ann Rheum Dis. 2012 Jun;71(6):989-92
22402142
Ann Rheum Dis. 2014 Mar;73(3):492-509
24161836
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39
22473917
J Rheumatol. 2004 Apr;31(4):645-8
15088287
J Clin Rheumatol. 2014 Aug;20(5):256-60
25036562
Ann Rheum Dis. 2009 Jul;68(7):1100-4
19060002
J Dermatolog Treat. 2015 Apr;26(2):188-90
24852821
Arthritis Rheum. 2008 Jan;58(1):73-81
18163521
Rheumatology (Oxford). 2003 Aug;42(8):1009-10
12869673
BioDrugs. 1997 Sep;8(3):164-75
18020507
Clin Exp Rheumatol. 2014 Jul-Aug;32(4):563-71
24983446
Ann Rheum Dis. 2009 Jul;68(7):1086-93
19033291
Ann Rheum Dis. 2004 Oct;63(10):1232-4
15361377
Arthritis Rheum. 2012 Sep;64(9):2824-35
22508468
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S102-9
21044441